4 results
To determine the relative bioavailability of pramipexole 4.5 mg tablets vs. 4.5 mg Sifrol in healthy subjects after up-titration.
Primary Objective: Assess the incidence of wound infections in patients treated with venous stenting and AV fistula and Prevena negative pressure wound therapy (NPWT).Secondary Objective(s): Assess the incidence of lymph leakage in patients treated…
Objective: Primary Aim (PHASE 1):To determine the prevalence of RLS in women with ALD.Secondary Aim (PHASE 2):To determine whether in a blinded crossover study a 8-week pramipexole treatment course will significantly reduce RLS symptoms compared to…
The primary aim of the trial is to demonstrate the non-inferiority of CSL222 (formerly AMT-061) (2 × 1013 gc/kg) during the 52 weeks following establishment of stable factor IX expression (months 6 to 18) post-treatment (CSL222 (formerly AMT-061))…